Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lattice Biologics Ltd LBLTF


Primary Symbol: V.LBL.H

Healthcare Biotechnology
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post... see more

Recent & Breaking News (TSXV:LBL.H)

Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease

Business Wire March 13, 2020

Lattice Biologics Announces Planned Debt-to-Equity Conversion

Business Wire March 11, 2020

LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2

Business Wire March 3, 2020

Lattice Biologics Ltd. Reports Q1 2020 Results

Business Wire February 28, 2020

Lattice Biologics Ltd. Reports Year End 2019 Results and Q1 Preliminary Q1 2020 Revenues

Business Wire January 28, 2020

Lattice Biologics Ltd. Reports Third Quarter 2019 Results

Business Wire August 29, 2019

Lattice Biologics Ltd. Reports Second Quarter 2019 Results

Business Wire May 31, 2019

Lattice Biologics Ltd. Reports First Quarter 2019 Results

Business Wire March 1, 2019

Lattice Biologics Ltd. Reports Year End 2018 Results

Business Wire January 29, 2019

Lattice Biologics Ltd. Reports Third Quarter 2018 Results

Business Wire August 30, 2018

Lattice Biologics Ltd. Reports Second Quarter 2018 Highlights

Business Wire May 30, 2018

Lattice Biologics Ltd. Announces Management Cease Trading Order is Revoked

Business Wire May 14, 2018

Lattice Biologics Ltd. Reports Fourth Quarter 2017, First Quarter 2018, and Year End 2017 Highlights

Business Wire April 30, 2018

Lattice Biologics Ltd. Announces Update to Management Cease Trade Order

Business Wire April 25, 2018

Lattice Biologics Ltd. Announces Update to Management Cease Trade Order

Business Wire April 11, 2018

Lattice Biologics Ltd. Announces Update to Management Cease Trade Order

Business Wire March 28, 2018

Update March 28, 2018: Lattice Biologics Ltd. Management Cease Trade Order

Business Wire March 28, 2018

Update March 14, 2018: Lattice Biologics Ltd. Management Cease Trade Order

Business Wire March 14, 2018

Update February 28, 2018: Lattice Biologics Ltd. Cease Trade Order

Business Wire February 28, 2018

Lattice Biologics Ltd. Announces Management Cease Trade Order

Business Wire February 14, 2018